STOCK TITAN

Teva to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences

Teva Pharmaceutical Industries (NYSE and TASE: TEVA) has announced that their President and CEO, Richard Francis, will deliver a presentation at the 43rd Annual J.P. Morgan Healthcare Conference. The presentation is scheduled for Monday, January 13, 2025, at 8:15 A.M. Pacific Time (11:15 A.M. Eastern Time).

Interested parties can access a live webcast of the presentation through Teva's Investor Relations website. An archived version will be made available within 24 hours after the live discussion concludes.

Teva Pharmaceutical Industries (NYSE e TASE: TEVA) ha annunciato che il loro Presidente e CEO, Richard Francis, terrà una presentazione alla 43ª Conferenza Sanitaria Annuale J.P. Morgan. La presentazione è programmata per lunedì 13 gennaio 2025, alle 8:15 P.M. Ora del Pacifico (11:15 A.M. Ora dell'Est).

Le parti interessate possono accedere a una trasmissione in diretta della presentazione attraverso il sito web delle Relazioni con gli Investitori di Teva. Una versione archiviata sarà disponibile entro 24 ore dopo la conclusione della discussione dal vivo.

Teva Pharmaceutical Industries (NYSE y TASE: TEVA) ha anunciado que su Presidente y CEO, Richard Francis, realizará una presentación en la 43.ª Conferencia Anual de Atención Médica J.P. Morgan. La presentación está programada para el lunes 13 de enero de 2025, a las 8:15 A.M. Hora del Pacífico (11:15 A.M. Hora del Este).

Las partes interesadas pueden acceder a una transmisión en vivo de la presentación a través del sitio web de Relaciones con Inversores de Teva. Una versión archivada estará disponible dentro de las 24 horas posteriores a la conclusión de la discusión en vivo.

테바 제약 산업 (NYSE 및 TASE: TEVA)는 그들의 사장 겸 CEO인 리차드 프랜시스제43회 JP모건 헬스케어 컨퍼런스에서 발표를 할 것이라고 발표했습니다. 발표는 2025년 1월 13일 월요일 오전 8:15 태평양 표준시 (동부 표준시 오전 11:15)로 예정되어 있습니다.

관심 있는 분들은 테바의 투자자 관계 웹사이트를 통해 발표의 생중계를 시청할 수 있습니다. 생중계가 끝난 후 24시간 이내에 아카이브된 버전이 제공될 예정입니다.

Teva Pharmaceutical Industries (NYSE et TASE: TEVA) a annoncé que son Président et CEO, Richard Francis, fera une présentation lors de la 43e Conférence Annuelle J.P. Morgan Healthcare. La présentation est prévue pour le lundi 13 janvier 2025, à 8h15 heure du Pacifique (11h15 heure de l'Est).

Les parties intéressées peuvent accéder à un webcast en direct de la présentation via le site web des Relations avec les Investisseurs de Teva. Une version archivée sera disponible dans les 24 heures suivant la fin de la discussion en direct.

Teva Pharmaceutical Industries (NYSE und TASE: TEVA) hat angekündigt, dass ihr Präsident und CEO, Richard Francis, eine Präsentation auf der 43. jährlichen J.P. Morgan Healthcare-Konferenz halten wird. Die Präsentation ist für Montag, den 13. Januar 2025, um 8:15 Uhr Pazifischer Zeit (11:15 Uhr Eastern Time) angesetzt.

Interessierte Parteien können über die Investor Relations-Website von Teva auf einen Live-Stream der Präsentation zugreifen. Eine archivierte Version wird innerhalb von 24 Stunden nach dem Ende der Live-Diskussion verfügbar sein.

Positive
  • None.
Negative
  • None.

TEL AVIV, Israel, Dec. 23, 2024 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva's President and CEO, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025. The presentation will begin at 8:15 A.M. Pacific Time (11:15 A.M. Eastern Time).

To access a live webcast of the presentation, visit Teva’s Investor Relations website at https://ir.tevapharm.com/Events-and-Presentations.

An archived version of the webcast will be available within 24 hours after the end of the live discussion.

About Teva

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is a global pharmaceutical leader, harnessing our generics expertise and stepping up innovation to continue the momentum behind the discovery, delivery, and expanded development of modern medicine. For over 120 years, Teva's commitment to bettering health has never wavered. Today, the company’s global network of capabilities enables its ~37,000 employees across 58 markets to push the boundaries of scientific innovation and deliver quality medicines to help improve health outcomes of millions of patients every day. To learn more about how Teva is all in for better health, visit www.tevapharm.com.

Cautionary Note Regarding Forward-Looking Statements

This document and the presentation at the conference may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on management’s current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include risks relating to: our ability to successfully compete in the marketplace including our ability to successfully execute our Pivot to Growth strategy, including to expand our innovative and biosimilar medicines pipeline and profitably commercialize the innovative medicines and biosimilar portfolio, whether organically or through business development, and to sustain and focus our portfolio of generics medicines; our substantial indebtedness; our business and operations in general including the impact of global economic conditions and other macroeconomic developments and the governmental and societal responses thereto; compliance, regulatory and litigation matters; other financial and economic risks; and other factors discussed in our Quarterly Report on Form 10-Q for the third quarter of 2024 and in our Annual Report on Form 10-K for the year ended December 31, 2023, including in the sections captioned "Risk Factors.” Forward-looking statements speak only as of the date on which they are made, and we assume no obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new information, future events or otherwise. You are cautioned not to put undue reliance on these forward-looking statements.

Teva Media Inquiries
TevaCommunicationsNorthAmerica@tevapharm.com

Teva Investor Relations Inquires
TevaIR@Tevapharm.com


FAQ

When is Teva (TEVA) presenting at the 2025 J.P. Morgan Healthcare Conference?

Teva will present on Monday, January 13, 2025, at 8:15 A.M. Pacific Time (11:15 A.M. Eastern Time).

How can investors watch Teva's (TEVA) J.P. Morgan Healthcare Conference presentation?

Investors can watch the presentation via live webcast on Teva's Investor Relations website at https://ir.tevapharm.com/Events-and-Presentations.

When will the replay of Teva's (TEVA) J.P. Morgan Healthcare Conference presentation be available?

An archived version of the webcast will be available within 24 hours after the end of the live discussion.

Who will represent Teva (TEVA) at the 2025 J.P. Morgan Healthcare Conference?

Richard Francis, Teva's President and CEO, will represent the company at the conference.

Teva Pharmaceutical Industries Limited American Depositary Shares

NYSE:TEVA

TEVA Rankings

TEVA Latest News

TEVA Stock Data

24.80B
1.13B
0%
57.83%
1.87%
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
Link
United States of America
TEL AVIV